Research Groups and R&D Platforms: Preclinical development
Research Group:
BioNanoMaterials research group
Jessica Rosenholm
Jessica.rosenholm[at]abo.fi
Pharmaceutical Sciences Laboratory,
Åbo Akademi University
Pharmaceutical Sciences Laboratory
Antibacterial, Biomedicine, Biopharmaceuticals, Biotechnology, Cancer, Diagnostics, Drug delivery, Drug solubility, Drug stability, Electron microscopy, Fluorescence spectroscopy, Formulation, FTIR or RAMAN spectroscopy, Imaging software, Infection, Lead optimization, Musculoskeletal disorders, Nanoparticles, Natural products, Organic compounds, Particle morphology, Particle size analysis, Personalized medicine, Pharmacy, Physico-chemical properties, Porosity, Powder flow characterization, Powder X-ray diffraction, Preclinical development, Screening, Skin diseases, Super-resolution imaging, Surface area, Synthetic chemistry, Thermal analysis, Zeta potential
Research Group:
Computer-aided drug design
Outi Salo-Ahen
osalo[at]abo.fi
Pharmaceutical Sciences and Structural Bioinformatics Laboratory,
Åbo Akademi University
Antibacterial, Bioinformatics, Biomolecular chemistry, Biopharmaceuticals, Cancer, Drug target, Hit to lead, Infection, Lead optimization, Medicinal chemistry, Molecular modelling, Natural Compounds, Natural products, Pharmacy, Preclinical development, Screening, Structural Biology
R&D Platform:
Bioanalytical Laboratory
Pharmacokinetic assessments and documentation of drug exposure are essential elements of all drug discovery and development endeavours. This research project aims to provide a technology platform for joint projects with investigators working in various fields of drug discovery and development. An automated system enabling frequent blood sampling from freely moving small laboratory animals and modern analytic instrumentation based on liquid chromatography and tandem mass spectrometry form the essential elements of this platform. Recent examples of the laboratory’s output are exemplified by the publications listed below, but a significant fraction of the laboratory’s projects represents contract research for small drug discovery companies. It is expected that this technology platform will help to promote both academic and commercial drug discovery and development activities in Finland.
Hit to lead, Lead optimization, Preclinical development
Research Group:
Mesoporous drug carriers/ Electrostatics / Pharmaceutical Physics
Jarno Salonen
jarno.salonen[at]utu.fi
Industrial Physics Laboratory,
University of Turku
Biopharmaceuticals, Cancer, Chemical Physics, Diabetes, Drug delivery, Drug solubility, Drug stability, Drug target, Electron microscopy, FTIR or RAMAN spectroscopy, Lead optimization, Microstructure analysis, Nanoparticles, NMR, Obesity, Particle size analysis, Pharmacy, Physico-chemical properties, Physics, Polymorph analysis, Porosity, Powder X-ray diffraction, Preclinical development, Surface area, Thermal analysis, Zeta potential
Research Group:
Radiopharmaceuticals for positron emission tomography (PET) imaging
Xiang-Guo Li
xiali[at]utu.fi
Turku PET Centre,
University of Turku
Antibodies, Assay development, Biomedicine, Cancer, Cardiovascular diseases, Clinical Chemistry, Drug delivery, Drug solubility, Drug stability, Formulation, Imaging, In Vivo Diagnostics, Infection, Inflammation, Medicinal chemistry, Metabolic diseases, Molecular diagnostics, Nanoparticles, Nucleic acids, Organic Chemistry, Organic compounds, Personalized medicine, PET, Pharmacy, Physico-chemical properties, Preclinical development, Synthetic chemistry
Research Group:
Incretin-based therapy in preclinical and early clinical type 1 diabetes
Jorma Toppari
jorma.toppari[at]utu.fi
Institute of Biomedicine,
University of Turku
Department of Pediatrics,
Turku University Hospital
Clinical development, Diabetes, Preclinical development
